Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Mark Peterson CPA who wrote (478)	1/26/1999 1:43:00 PM
From: Greg Jenkins	Read Replies (1) \| Respond to of 942

this just in: Warner-Lambert Increases Quarterly Dividend by 25% Business Wire - January 26, 1999 13:12 MORRIS PLAINS, N.J.--(BUSINESS WIRE)--January 26, 1999-- Warner-Lambert Company's Board of Directors today voted to increase the regular quarterly dividend rate by 25 percent, from 16 cents to 20 cents a share of common stock. Annualized, the new dividend is 80 cents. The increased first quarter dividend will be paid on March 10, 1999, to stockholders of record February 5, 1999. Warner-Lambert has increased its dividends paid every year since its stock was listed on the New York Stock Exchange in 1951. Additionally, Warner-Lambert has paid a dividend every year since 1926, ranking it among Standard & Poor's select list of companies with an unbroken record of dividends paid for at least 50 years. Warner-Lambert is a worldwide company devoted to discovering, developing, manufacturing, and marketing quality pharmaceutical, consumer health care, and confectionery products. It employs more than 40,000 people worldwide. CONTACT: Media Contact: Investor Contact: Jason Ford (973) 540-4268 Jack Howarth (973) 540-4874

To: Mark Peterson CPA who wrote (478)	1/26/1999 2:08:00 PM
From: Anthony Wong	Respond to of 942

Mark & thread, weekly prescription trends for WLA drugs: Diabetes: WLA's Rezulin new prescriptions market share increased from 8.9% to 9.0% this week. Novo Nordisk/Schering-Plough's Prandin increased 10 basis points to 1.8% this week. Cholesterol lowering: WLA's Lipitor gained 40 basis points to 42.9% market share of new prescriptions. MRK's Zocor increased from 25.7% last week to 26.0% this week. Bristol's Pravachol lost 40 basis points to 16.8%. Source: Merrill Lynch's 1/25 report

To: Mark Peterson CPA who wrote (478)	1/26/1999 4:11:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 942

16:02T Warner-Lambert May Buy 19.9% Stake If Agouron Terminates 16:01T Warner-Lambert Puts Agouron Termination Fee At $60M >WLA 16:00T Warner-Lambert To Swap 0.8108-0.93 Shrs For Each Agouron Shr 15:59T Warner-Lambert To Swap $60 Of Stk For Each Agouron Shr >WLA 15:58*T +Warner-Lambert To Acquire Agouron Pharma For $2.1B Stk >WLA

To: Mark Peterson CPA who wrote (478)	1/26/1999 4:55:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 942

Bloomberg: Warner-Lambert to Acquire Agouron Pharmaceuticals for US$2.1 Bln in Stock Bloomberg News January 26, 1999, 4:19 p.m. ET Warner-Lambert to Buy Agouron Pharmaceuticals for $2.1 Bln La Jolla, California, Jan. 26 (Bloomberg) - Warner-Lambert Co., one of the world's most profitable drugmakers, said it will buy Agouron Pharmaceuticals Inc., maker of the best-selling protease inhibitor for AIDS, for $2.1 billion in stock. The move will give Warner-Lambert its first AIDS drug -- Agouron's Viracept. That could provide Warner-Lambert with a hedge against a decline in sales of one of its top selling drugs, the diabetes pill Rezulin, which faces a federal safety review and new competition. ''By concentrating our resources and expanding into new therapeutic categories we will be well positioned to continue our impressive growth in the pharmaceutical sector,'' Warner-Lambert Chairman and Chief Executive Melvin R. Goodes said in a statement. Shares in Agouron were halted before the news was released. Earlier the the La Jolla, California-based biotechnology company rose 3 21/32 to 56 13/16. Viracept boosts the value of the company because Agouron held onto the rights to market it in the U.S., unlike many biotechnology companies who rely on big drugmakers to sell their drugs. That means Warner-Lambert won't have to share future profits from the AIDS drug. Warner-Lambert rose 1 to 68 1/2. The acquisition was announced just before the close of U.S. stock markets. --Jim Finkle in the San Francisco newsroom (415) 912-2996 with